Real-life effectiveness of iGlarLixi (insulin glargine 100 U/mL and lixisenatide) in people with type 2 diabetes according to prior insulin use

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00023001%3A_____%2F24%3A00084923" target="_blank" >RIV/00023001:_____/24:00084923 - isvavai.cz</a>

Výsledek na webu

<a href="https://dom-pubs.pericles-prod.literatumonline.com/doi/10.1111/dom.15609" target="_blank" >https://dom-pubs.pericles-prod.literatumonline.com/doi/10.1111/dom.15609</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1111/dom.15609" target="_blank" >10.1111/dom.15609</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Real-life effectiveness of iGlarLixi (insulin glargine 100 U/mL and lixisenatide) in people with type 2 diabetes according to prior insulin use

Popis výsledku v původním jazyce

Fixed-ratio combinations of a basal insulin and a glucagon-likepeptide-1 receptor agonist (GLP-1RA) have recently been incorporatedin the latest US and European guidelines for the management ofpeople with inadequately controlled type 2 diabetes (T2D), and glycatedhaemoglobin (HbA1c) &gt;2% above target or HbA1c value &gt;10%(&gt;85.8 mmol/mol). In addition to their effect on glycaemic control,the combination of a GLP-1RA and basal insulin in one injection mitigatesthe side effects of its individual components, such as the gastrointestinaladverse events (AEs), associated with GLP-1RAs and theweight gain associated with insulin use.iGlarLixi is the fixed-ratio combination of insulin glargine 100 U/mL (iGlar) and the GLP-1RA lixisenatide (Lixi), administered subcutaneouslyonce daily within 1 h before the most convenient meal.Although treatment with iGlarLixi achieved favourable clinical resultsin randomized controlled trials (RCTs), there are still limited dataon the real-life effectiveness and safety of initiating iGlarLixi ininsulin-naïve versus insulin-pretreated people with T2D.We have pooled data, therefore, from two observational studiesto evaluate the treatment outcomes of iGlarLixi in people withT2D inadequately controlled on non-insulin glucose-lowering therapy,with or without basal insulin, in the real-life setting.

Název v anglickém jazyce

Real-life effectiveness of iGlarLixi (insulin glargine 100 U/mL and lixisenatide) in people with type 2 diabetes according to prior insulin use

Popis výsledku anglicky

Fixed-ratio combinations of a basal insulin and a glucagon-likepeptide-1 receptor agonist (GLP-1RA) have recently been incorporatedin the latest US and European guidelines for the management ofpeople with inadequately controlled type 2 diabetes (T2D), and glycatedhaemoglobin (HbA1c) &gt;2% above target or HbA1c value &gt;10%(&gt;85.8 mmol/mol). In addition to their effect on glycaemic control,the combination of a GLP-1RA and basal insulin in one injection mitigatesthe side effects of its individual components, such as the gastrointestinaladverse events (AEs), associated with GLP-1RAs and theweight gain associated with insulin use.iGlarLixi is the fixed-ratio combination of insulin glargine 100 U/mL (iGlar) and the GLP-1RA lixisenatide (Lixi), administered subcutaneouslyonce daily within 1 h before the most convenient meal.Although treatment with iGlarLixi achieved favourable clinical resultsin randomized controlled trials (RCTs), there are still limited dataon the real-life effectiveness and safety of initiating iGlarLixi ininsulin-naïve versus insulin-pretreated people with T2D.We have pooled data, therefore, from two observational studiesto evaluate the treatment outcomes of iGlarLixi in people withT2D inadequately controlled on non-insulin glucose-lowering therapy,with or without basal insulin, in the real-life setting.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30202 - Endocrinology and metabolism (including diabetes, hormones)

Projekt

—

Návaznosti

N - Vyzkumna aktivita podporovana z neverejnych zdroju

Rok uplatnění

2024

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Diabetes, obesity and metabolism

ISSN

1462-8902

e-ISSN

1463-1326

Svazek periodika

26

Číslo periodika v rámci svazku

7

Stát vydavatele periodika

GB - Spojené království Velké Británie a Severního Irska

Počet stran výsledku

5

Strana od-do

2988-2992

Kód UT WoS článku

001216677500001

EID výsledku v databázi Scopus

2-s2.0-85191995772